Drug Combo Proves Powerful Against Lung Cancer Massena NY

A two-drug combination treatment in Massena proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Priti V Mandalaywala
(315) 268-8240
145 Market St
Potsdam, NY
PRITI MANDALAYWALA, MD
(315) 268-8240
145 Market Street
Potsdam, NY
Abboud Camille MD
(585) 275-5830
601 Elmwood Ave
Rochester, NY
Valentine Elizabeth MD
(518) 587-7670
31 Myrtle St
Saratoga Springs, NY
Sparacino Sharon Anp
(631) 727-8500
1333 E Main St
Riverhead, NY
Sun Liauw
315-268-9314
5 Lyon Pl
Potsdam, NY
John W Gebert
(814) 237-8627
145 Market St
Potsdam, NY
Priti Vijay Mandalaywala, MD
315-268-8240
145 Market St Ste 9
Potsdam, NY
Kamthan Arvind G MD M.R.C.R U.K. F.A.C.R
(845) 342-6464
225 Dolson Ave Ste 301
Middletown, NY
Cichanowicz Cynthia Anp
(631) 727-8500
1333 E Main St
Riverhead, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com